- Joined
- 1 April 2006
- Posts
- 509
- Reactions
- 0
Any thoughts on this one? - see article below. Sounds like a useful product now that we all live with paranoia about the brown marks on our skin... Although maybe we just grow some 'petty spurge' ourselves - what does this look like?
Chart looks interestng - has broken out from recent top, and now fighting long-term resistance levels, but if it passes $1 could have a run? MACD, DMI and vol all trending up.
PEP not expected to turn a profit till 2008, so plently of hurdles to clear on product development but does have $14m in the bank (burning about $10m pa)
Thoughts?
Chrs
Peplin's skin cancer gel trial a success
AAP Monday May 1, 2006, 6:18 pm
Early clinical trials of a new gel to treat skin cancer have returned promising results.
The gel, developed by Brisbane-based company Peplin, can be rubbed on to the skin to treat certain types of skin cancer.
Initial trials show just two applications of the PEP005 Topical gel on two consecutive days cleared up 71 per cent of basal cell carcinomas, or BCCs, the most common type of skin cancer.
The trials on 60 people throughout Australia built on an early study by Peplin in 2002 using the common garden weed, petty spurge.
"That was a very different study and that was just using the raw sap of petty spurge," said Michael Aldridge, Peplin's managing director and chief executive.
"This is the same company and we have now identified the molecule responsible for that activity and we have put that into a formal development program, formulated a gel and developed a manufacturing technology.
"We ran a phase one study in the US, two phase-two studies looking at sunspots, and this is our third phase-two study looking at basal cell carcinomas."
Mr Aldridge said it was the first time the molecule from petty spurge had been used to treat BCCs, which are usually surgically removed.
"We've seen some very, very impressive results," he said.
"This is the first time two days of therapy have shown to be effective in clearing skin cancers."
Peplin hopes to start phase-three studies of the gel later this year.
Australasian College of Dermatologists secretary Stephen Shumack said the results were promising.
"It is certainly encouraging," Dr Shumack said.
"This is a reasonable sort of result and I think from a dermatological point of view, it is the result that would be worthy of further investigation.
"It would be an addition to our current therapy."
BCCs develop from cells in the basal layer of the skin and account for 80 per cent of skin cancers.
A typical BCC sufferer is an older caucasian with a history of sun exposure.
The Cancer Council of Australia says 256,000 Australians were treated for BCCs in 2002.
Chart looks interestng - has broken out from recent top, and now fighting long-term resistance levels, but if it passes $1 could have a run? MACD, DMI and vol all trending up.
PEP not expected to turn a profit till 2008, so plently of hurdles to clear on product development but does have $14m in the bank (burning about $10m pa)
Thoughts?
Chrs
Peplin's skin cancer gel trial a success
AAP Monday May 1, 2006, 6:18 pm
Early clinical trials of a new gel to treat skin cancer have returned promising results.
The gel, developed by Brisbane-based company Peplin, can be rubbed on to the skin to treat certain types of skin cancer.
Initial trials show just two applications of the PEP005 Topical gel on two consecutive days cleared up 71 per cent of basal cell carcinomas, or BCCs, the most common type of skin cancer.
The trials on 60 people throughout Australia built on an early study by Peplin in 2002 using the common garden weed, petty spurge.
"That was a very different study and that was just using the raw sap of petty spurge," said Michael Aldridge, Peplin's managing director and chief executive.
"This is the same company and we have now identified the molecule responsible for that activity and we have put that into a formal development program, formulated a gel and developed a manufacturing technology.
"We ran a phase one study in the US, two phase-two studies looking at sunspots, and this is our third phase-two study looking at basal cell carcinomas."
Mr Aldridge said it was the first time the molecule from petty spurge had been used to treat BCCs, which are usually surgically removed.
"We've seen some very, very impressive results," he said.
"This is the first time two days of therapy have shown to be effective in clearing skin cancers."
Peplin hopes to start phase-three studies of the gel later this year.
Australasian College of Dermatologists secretary Stephen Shumack said the results were promising.
"It is certainly encouraging," Dr Shumack said.
"This is a reasonable sort of result and I think from a dermatological point of view, it is the result that would be worthy of further investigation.
"It would be an addition to our current therapy."
BCCs develop from cells in the basal layer of the skin and account for 80 per cent of skin cancers.
A typical BCC sufferer is an older caucasian with a history of sun exposure.
The Cancer Council of Australia says 256,000 Australians were treated for BCCs in 2002.
